| Full text | |
| Author(s): |
Lapa, A. T.
;
Postal, M.
;
Sinicato, N. A.
;
Bellini, B. S.
;
Fernandes, P. T.
;
Marini, R.
;
Appenzeller, S.
Total Authors: 7
|
| Document type: | Journal article |
| Source: | Lupus; v. 26, n. 5, SI, p. 478-483, APR 2017. |
| Web of Science Citations: | 4 |
| Abstract | |
Objective: To investigate serologic S100 beta protein levels in childhood-onset SLE patients (cSLE) and to elucidate their association with disease activity and neuropsychiatric (NP) manifestations. Methods: We included 71 cSLE patients (67 females; median age 18 years; range 9-37 and 53 (47 females; median age of 20 years; range 6-29) age and sex matched healthy controls. Neurological manifestations were analysed according to the American College of Rheumatology (ACR) criteria. Cognitive evaluation was performed in all participants using Wechsler Intelligence Scale for Children (WISC-III) and Wechsler Adult Intelligence Scale (WAIS), according to age, and validated in Portuguese. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Sera S100 beta protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Results: The median S100 beta protein level was 116.55 pg/mL (range 1.53-468.50) in cSLE and 54.98 pg/mL (range 0.69-181.00) in healthy controls (p<0.001). An association was observed between S100 beta protein and NP manifestations (p = 0.03). The S100 beta protein levels was associated with cognitive impairment in cSLE patients (p = 0.006). Conclusions: S100 beta protein levels are increased in cSLE with cognitive impairment. S100 beta may be considered a potential biomarker that underlies central nervous system (CNS) dysfunction, especially cognitive impairment. (AU) | |
| FAPESP's process: | 08/02917-0 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in systemic lupus erythematosus |
| Grantee: | Simone Appenzeller |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| FAPESP's process: | 11/03788-2 - Longitudinal evaluation of interleukins 4, 6, 10 and 12, interferon gamma and tumor necrosis factor alpha and laboratory and clinical associations in systemic lupus erythematosus |
| Grantee: | Mariana Postal Zink de Souza |
| Support Opportunities: | Scholarships in Brazil - Doctorate |